Physician profile
Fade Mahmoud
NPI 1568420966
$14,237.01
in general payments reported to CMS, 2019-2025
10 companies · $5,400 in 2025
The $5,400 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,171 · 2020: $1,630 · 2021: $1,260 · 2022: $2,626 · 2024: $150 · 2025: $5,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,400 · Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,400.00 |
| Food and Beverage | $149.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,223.82 | 2019-2022 | |
| Springworks Therapeutics, INC. | $5,400.00 | 2025 | Ogsiveo |
| Array Biopharma INC | $1,260.00 | 2021 | |
| Deciphera Pharmaceuticals INC. | $149.75 | 2024 | Qinlock |
| Regeneron Healthcare Solutions, INC. | $120.83 | 2019 | |
| Genzyme Corporation | $26.86 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.97 | 2019 | |
| Emd Serono, INC. | $14.40 | 2019 | |
| Seagen INC. | $12.28 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fade Mahmoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.